Lupin and Spektus Partner to Launch Antidepressant DeslaFlex in Canada
Filing Summary
Lupin Limited has entered into a license and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex in Canada. DeslaFlex, developed using Spektus’s proprietary Flexitab oral drug-delivery platform, aims to enhance Lupin’s central nervous system (CNS) portfolio. The agreement leverages Lupin’s commercial presence in Canada and Spektus’s expertise in innovative formulations. This collaboration is part of Lupin’s strategy to expand its CNS offerings and provide additional treatment options for Major Depressive Disorder. The partnership was announced on February 16, 2026.
Lupin Limited has signed a license and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex in Canada. The agreement, announced on February 16, 2026, involves the introduction of DeslaFlex, which is developed using Spektus’s proprietary Flexitab oral drug-delivery platform. This partnership is designed to expand Lupin’s central nervous system (CNS) portfolio in the Canadian market.
The financial terms of the agreement between Lupin and Spektus Pharma have not been disclosed in the filing. The focus of the agreement is on leveraging Lupin’s established commercial infrastructure in Canada to facilitate the distribution and marketing of DeslaFlex. The collaboration is expected to utilize Spektus’s capabilities in developing differentiated formulations to enhance the product’s market presence.
The scope of the agreement includes the commercialization of DeslaFlex, which is intended for the management of Major Depressive Disorder. The product is developed using the Flexitab platform, which provides enhanced dosing flexibility and improved patient compliance. This strategic partnership aims to establish a robust platform for future product launches in the CNS segment, aligning with a supportive regulatory environment in Canada.
The market context for this agreement involves Lupin’s strategy to strengthen its CNS portfolio by introducing physician-endorsed, value-added therapies. The collaboration with Spektus is part of Lupin’s broader commitment to advancing its presence in the Canadian healthcare market. The introduction of DeslaFlex is intended to provide patients and clinicians with additional options for personalized care in managing depression.
The timeline for the implementation of this agreement has not been specified in the filing. However, the announcement indicates that both companies are focused on transitioning from development to commercial execution. Lupin’s established commercial strength in Canada is expected to facilitate the timely introduction of DeslaFlex to the market.
Spektus Pharma is a growth-stage pharmaceutical company focused on developing and commercializing value-added CNS therapies. The company utilizes proprietary drug-delivery platforms to enhance dosing flexibility and patient compliance. Spektus aims to address unmet needs in depression, pain, and ADHD through its innovative formulations.
Lupin Limited is a global pharmaceutical leader specializing in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company operates in over 100 markets and has a strong presence in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, CNS, and women’s health. Lupin is committed to improving patient health outcomes through its subsidiaries and strategic partnerships.